# A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

> **NCT06496178** · PHASE3 · RECRUITING · sponsor: **Merus B.V.** · enrollment: 600 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Petosemtamab
- **DRUG:** Investigator's Choice
- **DRUG:** Investigator's Choice
- **DRUG:** Investigator's Choice

## Key facts

- **NCT ID:** NCT06496178
- **Lead sponsor:** Merus B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-25
- **Primary completion:** 2028-02
- **Final completion:** 2029-03
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06496178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06496178, "A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT06496178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*